Skip Navigation

JNCI Journal of the National Cancer Institute 2004 96(12):891; doi:10.1093/jnci/96.12.891-b
© 2004 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Zielinski, S. L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Zielinski, S. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 Oxford University Press

Press Release

Study Investigates Breast Cancer Resistance to Tamoxifen and Possible Way to Reverse It

Sarah L. Zielinski

jncimedia@oupjournals.org
301-841-1287
Journal of the National Cancer Institute

The first 10% of the full text of this article appears below.

A new study has found a possible mechanism for tamoxifen resistance in breast cancer and provides evidence that another cancer drug—gefitinib (Iressa)—may be able to restore tamoxifen’s anticancer activity. The study appears in the June 16 issue of the Journal of the National Cancer Institute.

Although adjuvant . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?